Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Current Report on Form 8-K dated September 21, 2022, reporting arrangements with Andrew L. Pecora, M.D., following his resignation as the company’s President effective August 31, 2022.
Material Agreements and Compensation
- Celularity entered into a consulting agreement with Dr. Pecora effective September 21, 2022. He will advise management regarding the company’s clinical development programs for a monthly fee of $10,000.
- The consulting agreement has an initial six-month term and will automatically renew for one additional six-month term unless either party provides timely notice of non-renewal.
- Celularity also entered into a scientific and clinical advisor agreement with Dr. Pecora, effective September 1, 2022. He will serve as co-chair of the company’s scientific and clinical advisory board.
- Under the advisor agreement, Dr. Pecora will receive a monthly fee of $10,000 and a one-time grant of restricted stock units valued at $125,000 on the grant date.
- The RSUs vest in four successive equal annual installments from the grant date.
- The advisor agreement has a one-year term and may be renewed for successive one-year terms by mutual agreement.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Outlook, Risks, and Unusual Items
The agreements create recurring cash compensation obligations totaling $20,000 per month while both arrangements are in effect, in addition to the $125,000 equity award. The filing does not provide broader financial guidance or an updated business outlook.
The agreements’ complete terms were not included in the filing text; Celularity stated that it intended to file them as exhibits to its Form 10-Q for the quarter ended September 30, 2022.
Key Facts to Verify
- Confirm the final filed versions of the consulting and scientific and clinical advisor agreements.
- Verify the RSU grant date, number of shares, vesting provisions, and accounting expense.
- Review subsequent filings for renewals, termination, or changes to Dr. Pecora’s compensation arrangements.
- Assess the effect of the recurring advisory fees and equity compensation on future operating expenses and share dilution.